{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:18:58Z","timestamp":1753888738385,"version":"3.41.2"},"reference-count":36,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,7]]},"DOI":"10.20945\/2359-4292-2022-0480","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T14:53:02Z","timestamp":1715179982000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of sustained virologic response on glucose parameters among patients with chronic hepatitis C treated with direct-acting antivirals"],"prefix":"10.20945","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8739-7674","authenticated-orcid":false,"given":"F\u00e1bia","family":"Benetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4128-6936","authenticated-orcid":false,"given":"Alexandre de","family":"Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1347-0816","authenticated-orcid":false,"suffix":"J\u00fanior","given":"Italo","family":"de Maman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5473-3184","authenticated-orcid":false,"given":"Cristina Coelho Borges","family":"Cheinquer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2907-9210","authenticated-orcid":false,"given":"Fernando","family":"Herz Wolff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2463-6965","authenticated-orcid":false,"given":"Hugo","family":"Cheinquer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8510","reference":[{"issue":"5","key":"key20240508105256_B1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study","volume":"7","author":"Polaris Observatory HCV Collaborators","year":"2022","unstructured":"1 Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022 May;7(5):396-415. doi: 10.1016\/S2468-1253(21)00472-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"key20240508105256_B2","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jhep.2014.08.003","article-title":"Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases","volume":"61","author":"Negro","year":"2014","unstructured":"2 Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol. 2014 Nov;61(1 Suppl):S69-78. doi: 10.1016\/j.jhep.2014.08.003.","journal-title":"J Hepatol"},{"issue":"7","key":"key20240508105256_B3","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","article-title":"Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden","volume":"150","author":"Younossi","year":"2016","unstructured":"3 Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology. 2016 Jun;150(7):1599-608. doi: 10.1053\/j.gastro.2016.02.039.","journal-title":"Gastroenterology"},{"issue":"2","key":"key20240508105256_B4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.23736\/S0026-4806.20.07129-3","article-title":"Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: Mechanisms and management","volume":"112","author":"Nevola","year":"2021","unstructured":"4 Nevola R, Acierno C, Pafundi PC, Adinolfi LE. Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: Mechanisms and management. Minerva Med. 2021 Apr;112(2):188-200. doi: 10.23736\/S0026-4806.20.07129-3.","journal-title":"Minerva Med"},{"issue":"7","key":"key20240508105256_B5","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/cid\/cir076","article-title":"Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More","volume":"52","author":"Pearlman","year":"2011","unstructured":"5 Pearlman BL, Traub N. Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More. Clin Infect Dis. 2011 Apr 1;52(7):889-900. doi: 10.1093\/cid\/cir076.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"key20240508105256_B6","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.jhep.2020.08.006","article-title":"Hepatic benefits of HCV cure","volume":"73","author":"Calvaruso","year":"2020","unstructured":"6 Calvaruso V, Crax\u00ec A. Hepatic benefits of HCV cure. J Hepatol. 2020 Dec;73(6):1548-56. doi: 10.1016\/j.jhep.2020.08.006.","journal-title":"J Hepatol"},{"issue":"5","key":"key20240508105256_B7","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity","volume":"74","author":"Krassenburg","year":"2021","unstructured":"7 Krassenburg LAP, Maan R, Ramji A, Manns MP, Cornberg M, Wedemeyer H, et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol. 2021 May;74(5):1053-63. doi: 10.1016\/j.jhep.2020.11.021.","journal-title":"J Hepatol"},{"key":"key20240508105256_B8","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/MEG.0000000000002240","article-title":"Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals","volume":"33","author":"Alem","year":"2021","unstructured":"8 Alem SA, Eletreby R, Abdellatif Z, Ramadan A, Nagy A, AbdAllah M, et al. Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals. Eur J Gastroenterol Hepatol. 2021 Dec 1;33(Suppl 1):746-52. doi: 10.1097\/MEG.0000000000002240.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"8","key":"key20240508105256_B9","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/jvh.13295","article-title":"The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk","volume":"27","author":"Janjua","year":"2020","unstructured":"9 Janjua NZ, Wong S, Darvishian M, Butt ZA, Yu A, Binka M, et al. The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk. J Viral Hepat. 2020 Aug;27(8):781-93. doi: 10.1111\/jvh.13295.","journal-title":"J Viral Hepat"},{"issue":"9","key":"key20240508105256_B10","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1111\/liv.14905","article-title":"Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus\/diabetic individuals with chronic hepatitis or with cirrhosis","volume":"41","author":"Cacciola","year":"2021","unstructured":"10 Cacciola I, Russo G, Filomia R, Pitrone C, Caccamo G, Giandalia A, et al. Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus\/diabetic individuals with chronic hepatitis or with cirrhosis. Liver Int. 2021 Sep;41(9):2059-67. doi: 10.1111\/liv.14905.","journal-title":"Liver Int"},{"issue":"7","key":"key20240508105256_B11","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/jgh.14067","article-title":"Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients","volume":"33","author":"Adinolfi","year":"2018","unstructured":"11 Adinolfi LE, Nevola R, Guerrera B, D'Alterio G, Marrone A, Giordano M, et al. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. J Gastroenterol Hepatol. 2018 Jul;33(7):1379-82. doi: 10.1111\/jgh.14067.","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"key20240508105256_B12","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc17-0485","article-title":"Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus","volume":"40","author":"Hum","year":"2017","unstructured":"12 Hum J, Jou JH, Green PK, Berry K, Lundblad J, Hettinger BD, et al. Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus. Diabetes Care. 2017 Sep;40(9):1173-80. doi: 10.2337\/dc17-0485.","journal-title":"Diabetes Care"},{"issue":"6","key":"key20240508105256_B13","first-page":"775","article-title":"Treatment of Hepatitis C Virus and Long-Term Effect on Glycemic Control","volume":"26","author":"Andres","year":"2020","unstructured":"13 Andres J, Barros M, Arutunian M, Zhao H. Treatment of Hepatitis C Virus and Long-Term Effect on Glycemic Control. J Manag Care Spec Pharm. 2020 Jun;26(6):775-81. doi: 10.18553\/jmcp.2020.26.6.775.","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"key20240508105256_B14","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/liv.13669","article-title":"Hepatitis C virus eradication by direct antiviral agents improves glucose tolerance and reduces post-load insulin resistance in nondiabetic patients with genotype 1","volume":"38","author":"Salomone","year":"2018","unstructured":"14 Salomone F, Catania M, Montineri A, Bertino G, Godos J, Rizzo L, et al. Hepatitis C virus eradication by direct antiviral agents improves glucose tolerance and reduces post-load insulin resistance in nondiabetic patients with genotype 1. Liver Int. 2018 Jul;38(7):1206-11. doi: 10.1111\/liv.13669.","journal-title":"Liver Int"},{"issue":"3","key":"key20240508105256_B15","first-page":"264","article-title":"The impact of direct-acting antiviral treatment on glycemic homeostasis in patients with chronic hepatitis C","volume":"67","author":"Sacco","year":"2021","unstructured":"15 Sacco M, Saracco GM. The impact of direct-acting antiviral treatment on glycemic homeostasis in patients with chronic hepatitis C. Minerva Gastroenterol (Torino). 2021 Sep;67(3):264-72. doi: 10.23736\/S2724-5985.21.02835-X.","journal-title":"Minerva Gastroenterol (Torino)"},{"issue":"2","key":"key20240508105256_B16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/jgh3.12474","article-title":"Eradication of hepatitis C virus with direct-acting antivirals improves glycemic control in diabetes: A multicenter study","volume":"5","author":"Takahashi","year":"2021","unstructured":"16 Takahashi H, Nakahara T, Kogiso T, Imajo K, Kessoku T, Kawaguchi T, et al.; Japan Study Group of NAFLD (JSG-NAFLD). Eradication of hepatitis C virus with direct-acting antivirals improves glycemic control in diabetes: A multicenter study. JGH Open. 2021 Dec 19;5(2):228-34. doi: 10.1002\/jgh3.12474.","journal-title":"JGH Open"},{"key":"key20240508105256_B17","doi-asserted-by":"crossref","first-page":"6438753","DOI":"10.1155\/2020\/6438753","article-title":"Impact of Treatment with Direct Acting Antiviral Drugs on Glycemic Control in Patients with Hepatitis C and Diabetes Mellitus","volume":"2020","author":"Mada","year":"2020","unstructured":"17 Mada PK, Malus ME, Parvathaneni A, Chen B, Castano G, Adley S, et al. Impact of Treatment with Direct Acting Antiviral Drugs on Glycemic Control in Patients with Hepatitis C and Diabetes Mellitus. Int J Hepatol. 2020 Jan 13;2020:6438753. doi: 10.1155\/2020\/6438753.","journal-title":"Int J Hepatol"},{"issue":"3","key":"key20240508105256_B18","first-page":"182","article-title":"Hepatitis C disease burden and strategies for elimination by 2030 in Brazil","volume":"23","author":"Benzaken","year":"2019","unstructured":"18 Benzaken AS, Girade R, Catapan E, Pereira GFM, Almeida EC, Vivaldini S, et al. Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach. Braz J Infect Dis. 2019 May-Jun;23(3):182-90. doi: 10.1016\/j.bjid.2019.04.010.","journal-title":"A mathematical modeling approach. Braz J Infect Dis"},{"issue":"3","key":"key20240508105256_B19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1590\/s0004-2803.201800000-69","article-title":"Insulin resistance reduction after sustained virological response with direct acting antiviral: not every population improves","volume":"55","author":"Andrade","year":"2018","unstructured":"19 Andrade VG, Yamashiro FDS, Oliveira CV, Moreira A, Winckler FC, Silva GF. Insulin resistance reduction after sustained virological response with direct acting antiviral: not every population improves. Arq Gastroenterol. 2018 Jul-Sep;55(3):274-8. doi: 10.1590\/S0004-2803.201800000-69.","journal-title":"Arq Gastroenterol"},{"issue":"12","key":"key20240508105256_B20","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1590\/1806-9282.20210752","article-title":"Hepatitis C virus eradication on glycemic control and insulin resistance","volume":"67","author":"Carvalhal","year":"2021","unstructured":"20 Carvalhal MML, Dias JLL, Gomes DL, Quaresma JAS. Hepatitis C virus eradication on glycemic control and insulin resistance. Rev Assoc Med Bras (1992). 2021 Dec;67(12):1821-4. doi: 10.1590\/1806-9282.20210752.","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"key20240508105256_B21","first-page":"S14","volume-title":"Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care","author":"American Diabetes Association. 2","year":"2020","unstructured":"21 American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31. doi: 10.2337\/dc20-S002."},{"journal-title":"Brazilian Ministry of Health","author":"Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Hepatite C e Coinfec\u00e7\u00f5es. [Internet]","key":"key20240508105256_B22","unstructured":"22 Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Hepatite C e Coinfec\u00e7\u00f5es. [Internet]. Brazilian Ministry of Health. [Uptaded 2015]. Available from: https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/protocolo_clinico_diretrizes_terapeuticas_hepatite_c_coinfeccoes.pdf"},{"issue":"2","key":"key20240508105256_B23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jmv.24954","article-title":"Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents","volume":"90","author":"Ciancio","year":"2018","unstructured":"23 Ciancio A, Bosio R, Bo S, Pellegrini M, Sacco M, Vogliotti E, et al. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. J Med Virol. 2018 Feb;90(2):320-7. doi: 10.1002\/jmv.24954.","journal-title":"J Med Virol"},{"issue":"3","key":"key20240508105256_B24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000500963","article-title":"Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications","volume":"35","author":"Sandmann","year":"2019","unstructured":"24 Sandmann L, Schulte B, Manns MP, Maasoumy B. Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications. Visc Med. 2019 Jun;35(3):161-70. doi: 10.1159\/000500963.","journal-title":"Visc Med"},{"issue":"6","key":"key20240508105256_B25","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1665-2681(19)31291-8","article-title":"Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients","volume":"12","author":"P\u00e9res","year":"2013","unstructured":"25 P\u00e9res DP, Cheinquer H, Wolf FH, Cheinquer N, Falavigna M, P\u00e9res LD. Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients. Ann Hepatol. 2013 Nov-Dec;12(6):871-5. PMID: 24114816.","journal-title":"Ann Hepatol"},{"issue":"3","key":"key20240508105256_B26","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jhep.2020.03.031","article-title":"DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort","volume":"73","author":"Verna","year":"2020","unstructured":"26 Verna EC, Morelli G, Terrault NA, Lok AS, Lim JK, Di Bisceglie AM, et al. DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. J Hepatol. 2020 Sep;73(3):540-8. doi: 10.1016\/j.jhep.2020.03.031.","journal-title":"J Hepatol"},{"issue":"6","key":"key20240508105256_B27","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.aohep.2019.08.001","article-title":"Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil","volume":"18","author":"Lobato","year":"2019","unstructured":"27 Lobato CMO, Codes L, Silva GF, Souza AFM, Coelho HSM, Pedroso MLA, et al.; Members of the Brazilian Real-Life Study about HCV treatment; Members of the Brazilian Real-Life Study about HCV treatment. Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil. Ann Hepatol. 2019 Nov-Dec;18(6):849-54. doi: 10.1016\/j.aohep.2019.08.001.","journal-title":"Ann Hepatol"},{"key":"key20240508105256_B28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.atherosclerosis.2020.01.010","article-title":"Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study","volume":"296","author":"Adinolfi","year":"2020","unstructured":"28 Adinolfi LE, Petta S, Fracanzani AL, Coppola C, Narciso V, Nevola R, et al. Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. Atherosclerosis. 2020 Mar;296:40-7. doi: 10.1016\/j.atherosclerosis.2020.01.010.","journal-title":"Atherosclerosis"},{"key":"key20240508105256_B29","doi-asserted-by":"crossref","first-page":"799382","DOI":"10.3389\/fendo.2021.799382","article-title":"Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients","volume":"12","author":"Cheng","year":"2022","unstructured":"29 Cheng CH, Chu CY, Chen HL, Lin IT, Wu CH, Lee YK, et al. Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients. Front Endocrinol (Lausanne). 2022 Jan 13;12:799382. doi: 10.3389\/fendo.2021.799382.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"key20240508105256_B30","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.3390\/cells10112934","article-title":"Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study","volume":"10","author":"Lee","year":"2021","unstructured":"30 Lee H, Chien RN, Pao LH, Kuo CJ, Huang PH, Chang ML. Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study. Cells. 2021 Oct 28;10(11):2934. doi: 10.3390\/cells10112934.","journal-title":"Cells"},{"issue":"27","key":"key20240508105256_B31","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"Feld","year":"2015","unstructured":"31 Feld JJ, Jacobson IM, H\u00e9zode C, Asselah T, Ruane PJ, Gruener N, et al.; ASTRAL-1 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015 Dec 31;373(27):2599-607. doi: 10.1056\/NEJMoa1512610.","journal-title":"N Engl J Med"},{"issue":"3","key":"key20240508105256_B32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/liv.13534","article-title":"Sofosbuvir\/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis","volume":"38","author":"Asselah","year":"2018","unstructured":"32 Asselah T, Bourgeois S, Pianko S, Zeuzem S, Sulkowski M, Foster GR, et al. Sofosbuvir\/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. Liver Int. 2018 Mar;38(3):443-50. doi: 10.1111\/liv.13534.","journal-title":"Liver Int"},{"issue":"1","key":"key20240508105256_B33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.27095","article-title":"HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S","volume":"60","author":"Kanwal","year":"2014","unstructured":"33 Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014 Jul;60(1):98-105. doi: 10.1002\/hep.27095.","journal-title":"Veterans with HCV. Hepatology"},{"issue":"2","key":"key20240508105256_B34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/jcm11020379","article-title":"HCV Genotype Has No Influence on the Incidence of Diabetes-EpiTer Multicentre Study","volume":"11","author":"Rajewski","year":"2022","unstructured":"34 Rajewski P, Zar\u0119bska-Michaluk D, Janczewska E, Gietka A, Mazur W, Tudrujek-Zdunek M, et al. HCV Genotype Has No Influence on the Incidence of Diabetes-EpiTer Multicentre Study. J Clin Med. 2022 Jan 13;11(2):379. doi: 10.3390\/jcm11020379.","journal-title":"J Clin Med"},{"issue":"7","key":"key20240508105256_B35","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s11606-020-05782-6","article-title":"Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals","volume":"35","author":"Do","year":"2020","unstructured":"35 Do A, Esserman DA, Krishnan S, Lim JK, Taddei TH, Hauser RG, et al. Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. J Gen Intern Med. 2020 Jul;35(7):2025-34. doi: 10.1007\/s11606-020-05782-6.","journal-title":"J Gen Intern Med"},{"issue":"9","key":"key20240508105256_B36","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1055\/s-0043-112656","article-title":"Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up","volume":"55","author":"Schlevogt","year":"2017","unstructured":"36 Schlevogt B, Deterding K, Port K, Siederdissen CHZ, Sollik L, Kirschner J, et al. Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up. Z Gastroenterol. 2017 Sep;55(9):848-56. doi: 10.1055\/s-0043-112656.","journal-title":"Z Gastroenterol"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T14:53:17Z","timestamp":1715179997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/impact-of-sustained-virologic-response-on-glucose-parameters-among-patients-with-chronic-hepatitis-c-treated-with-direct-acting-antivirals\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":36,"alternative-id":["10.20945\/2359-4292-2022-0480"],"URL":"https:\/\/doi.org\/10.20945\/2359-4292-2022-0480","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"type":"print","value":"2359-3997"},{"type":"electronic","value":"2359-4292"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e220480"}}